Oct 10, 2019
FDA Grants Ofev® Breakthrough Therapy Designation for Chronic Fibrosing ILDs with a Progressive Phenotype
Oct 09, 2019
New data showed OFEV® (nintedanib) slows decline of lung function in broad range of chronic fibrosing interstitial lung diseases with a progressive phenotype(1)
Oct 02, 2019
Xylyx Bio announces development of disease-specific cell culture products to accelerate anti-fibrotic drug discovery and screening
Sep 06, 2019
FDA approves first treatment for patients with rare type of lung disease
Sep 04, 2019
Three Lakes Partners And Pulmonary Fibrosis Foundation Partner In Fight Against Pulmonary Fibrosis
Jul 29, 2019
PF Warriors and Responsum Health Announce Strategic Alliance
Jul 25, 2019
FDA Advisory Committee Recommends Approval of Ofev® for the Treatment of Systemic Sclerosis Associated ILD
Jun 27, 2019
Pliant Therapeutics Reports Positive Results of Phase 1b Clinical Study Supporting Advancement of PLN-74809 for Treatment of Idiopathic Pulmonary Fibrosis
Jun 17, 2019
Promedior Presents Positive Data from a Phase 2 Study of PRM-151 in Myelofibrosis Patients Failed/Ineligible for Ruxolitinib at the 24th European Hematology Association Annual Congress
May 30, 2019
Pulmonary Fibrosis Patient Registry Research Presented At American Thoracic Society Conference
May 22, 2019
Prometic presents new PBI-4050 and Ryplazim(TM) (plasminogen) data on lung fibrosis at the 2019 ATS Conference
May 20, 2019
Phase III study showed Ofev® slows the loss of pulmonary function in people living with systemic sclerosis associated ILD
May 20, 2019
Promedior Announces Positive Long-term Safety and Efficacy Data from Open Label Extension Study of PRM-151 in Idiopathic Pulmonary Fibrosis
May 19, 2019
Bridge Biotherapeutics Announces Data Presentation from First-in-Human Study of BBT-877 for Idiopathic Pulmonary Fibrosis
Apr 18, 2019
Indalo Therapeutics Initiates Dosing in Phase 1 Clinical Trial of Lead Antifibrotic Drug Candidate IDL-2965
Apr 15, 2019
Research And Peer Support Drive Conference On Life-Threatening Lung Disease
Apr 09, 2019
Pliant Therapeutics Reports Positive Results of Phase 1 Clinical Study Support Advancement of PLN-74809 for Idiopathic Pulmonary Fibrosis
Mar 20, 2019
Access To Care Improves For Patients With Complex Lung Disease
Mar 18, 2019
Boehringer Ingelheim announces FDA and EMA regulatory submission for nintedanib in systemic sclerosis associated ILD
Mar 06, 2019
Pulmonary Fibrosis Foundation Updates Warning On Stem Cell Therapies Outside Clinical Trials